Not a good buy right now for an impatient investor: price is sitting on/near key support (S1 ~2.28) with weakening momentum (MACD histogram negative and expanding).
Despite bullish longer-term moving averages, the near-term tape looks fragile and options flow is skewed bearish today (put-heavy volume).
Wall Street is bullish (recent Buy/Overweight initiations with $7–$9 targets) and hedge funds have been accumulating, but without a proprietary signal today and with earnings approaching (2026-02-18 pre-market), the risk/reward right now is not compelling.
Trend/MAs: Bullish structure on moving averages (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been constructive.
Momentum: MACD histogram -0.0193 (below zero) and negatively expanding → bearish/weakening momentum in the near term.
RSI: RSI_6 at 39.26 → leaning weak (not oversold), so no strong “bounce” signal yet.
Levels: Immediate support S1 ~2.28 (price ~2.29 pre-market). If it loses 2.28, next support S2 ~2.084. Upside confirmation would be reclaiming pivot ~2.597, then R1 ~2.914.
Pattern/near-term odds (model): ~50% chance of only modest upside near term (+1.2% next day; +2.76% next week), with flat-to-slightly negative month bias (-0.31%).
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning: Open interest is overwhelmingly calls (call OI 11,173 vs put OI 50) → longer-dated positioning looks bullish/speculative.
Today’s sentiment: Volume Put-Call Ratio 3.23 (puts dominating today’s volume) → near-term traders are leaning defensive/bearish.
Volatility: 30D IV 108.76 vs HV 69.57 → options imply big moves, but IV percentile ~3.98 / IV rank ~4.5 indicates IV is low relative to its own history (options relatively “cheap” vs recent extremes).
Activity spike: Today’s volume (131) is far above avg (today vs 30D avg ~32.83), signaling elevated attention into the session.
Technical Summary
Sell
2
Buy
10
Positive Catalysts
Analyst support: Recent initiations are strongly bullish (Buy/Overweight) with large upside targets ($7 and $9).
Institutional flow: Hedge funds are buying, with reported buying amount up ~2167% over the last quarter.
Event catalyst: Upcoming QDEC 2025 earnings on 2026-02-18 (pre-market) can act as a volatility/catalyst window.
Pipeline narrative (from analyst notes): Lead gene therapy programs cited as showing early efficacy/promising preclinical data in high unmet-need indications.
Neutral/Negative Catalysts
increases downside risk if support breaks.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $3.079M, down -20.38% YoY → top-line contraction.
Net income: -$17.454M (still a sizable loss); the snapshot indicates YoY change of +131.92% (directionally still negative and not showing profitability).
EPS: -0.25, down -13.79% YoY → per-share losses widened.
Gross margin: 100% (typical for certain biotech revenue mixes), but profitability remains deeply negative due to operating spend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
2025-11-25: Piper Sandler initiated Overweight, PT $7; highlighted early efficacy for OPGx-LCA5 and promising preclinical data for OPGx-BEST1.
2025-12-09: B. Riley initiated Buy, PT $9.
Trend: Ratings are net bullish with rising Street attention via initiations; price targets imply substantial upside from ~$2.29.
Wall Street pros: strong upside potential tied to gene therapy pipeline and unmet need.
Wall Street cons: limited evidence of near-term financial improvement (revenue down, losses persist) and the stock likely trades on catalysts rather than steady fundamentals.
Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8 USD with a low forecast of 6 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast IRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRD is 8 USD with a low forecast of 6 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.580
Low
6
Averages
8
High
9
Current: 2.580
Low
6
Averages
8
High
9
B. Riley
NULL -> Buy
initiated
$9
AI Analysis
2025-12-09
Reason
B. Riley
Price Target
$9
AI Analysis
2025-12-09
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Opus Genetics with a Buy rating and $9 price target.
Piper Sandler
Overweight
initiated
$7
2025-11-25
Reason
Piper Sandler
Price Target
$7
2025-11-25
initiated
Overweight
Reason
Piper Sandler initiated coverage of Opus Genetics with an Overweight rating and $7 price target. The company has demonstrated early efficacy data for its lead gene therapy program, OPGx-LCA5, in Leber congenital amaurosis type 5, where there are currently no treatment options and a high unmet need, the analyst tells investors in a research note. In addition, Piper says Opus' second gene therapy program, OPGx-BEST1 for BEST1-related inherited retinal diseases, has promising preclinical data.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IRD
